Comment on: Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta‐analysis DOI Creative Commons
Cong Yin, Juan Li, Lin Yuan

et al.

Clinical Cardiology, Journal Year: 2023, Volume and Issue: 46(5), P. 584 - 584

Published: March 2, 2023

With great interest, we read the article by Shang et al.1 published in August 2022 Clinical Cardiology. The authors performed a meta-analysis and concluded that “tolvaptan treatment significantly improved patient-assessed dyspnea early persistently patients with acute heart failure.” At outset, would like to congratulate for writing an informative novelty. Nevertheless, have several suggestions queries communicate authors. First, evaluate quality of included studies using Detsky Quality Assessment Scale. Although this scale is used risk bias assessment, National Institutes Health Cochrane Library suggest qualitative analysis question. tool has become standard method experimental studies.2 Moreover, selection more definite approaches, such as GRADE (Grading Recommendations Assessment, Development Evaluation) approach, highly suggested define level evidence. Second, mentioned four databases clinicaltrials.gov were searched study, no language restrictions. It made results convincing if had other Wanfang Data, Scopus, China Knowledge Infrastructure (CNKI), World Organization Trials Portal (ICTRP) obtain literature Chinese or language. chances articles languages being ignored may be further narrowed. Third, did not register protocol International Prospective Register Systematic Reviews (PROSPERO). Protocol registration now recognized desirable approach enhance maintain transparency process assist minimizing selective outcome reporting bias.3 Fourth, need detailed retrieval strategies repeat meta-analysis. But paper provide it. And according requirements Preferred Reporting Items reviews Meta-Analyses (PRISMA), should provided article.4 same time, PRISMA been updated 2020 reflect recent advances systematic review methodology terminology,3 can use latest statement complete meta-analyses. In summary, learned author's standardized process. We hope discuss about above doubts. think our discussion make conclusion rigorous. declare conflict interest.

Language: Английский

Anakinra was not associated with lower mortality in hospitalised COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials DOI
Wenli Shang, Yingying Zhang,

Guizuo Wang

et al.

Reviews in Medical Virology, Journal Year: 2023, Volume and Issue: 33(2)

Published: Jan. 4, 2023

The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. This meta-analysis aimed determine efficacy of anakinra on mortality in patients with COVID-19. A systematic search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov, without language restrictions. Randomized controlled trials treatment COVID-19 anakinra, compared placebo or blank, were reviewed. Studies pooled risk ratios (RRs), 95% confidence intervals (CIs). Five (enrolling 1859 participants) met inclusion criteria. There no statistically significant difference 14-day (RR 0.78, CI 0.43-1.39; P = 0.40), 28-day 1.06, 0.89-1.26; 0.51), 90-day 1.01, 0.73-1.39; 0.97) between two groups. Sensitivity analyses further confirmed these results. Anakinra not associated reduced hospitalised probably should be used routinely patients.

Language: Английский

Citations

11
Arginine vasopressin and copeptin: comparative review and perspective in veterinary medicine DOI Creative Commons
Mathieu Victor Paulin, Thomas Schermerhorn, Suraj Unniappan

et al.

Frontiers in Veterinary Science, Journal Year: 2025, Volume and Issue: 12

Published: March 14, 2025

Although arginine vasopressin (AVP) deficiency, AVP resistance, and primary polydipsia are important causes of polyuria (PUPD), measurement has never been implemented as a routine diagnostic test for patient care in either human or veterinary medicine, due to significant challenges with the methodologic reliability laboratory assays measuring AVP. Responses modified water deprivation and/or desmopressin acetate trial have used indirect markers deficiency resistance. However, interpretations these tests can be especially challenging cases partial Over past decade, plasma copeptin (CoP), glycopeptide comprising C-terminal part preprohormone, mostly replaced humans. When combined CoP-based stimulation tests, such hypertonic saline CoP offers excellent accuracy diagnosis differentiation central diabetes insipidus (DI), nephrogenic DI, In dogs, recently measured saliva serum using canine enzyme-linked immunosorbent assays. This review will provide an update on physiologic regulation production secretion, limitations its well summary indications performance medicine date. is purpose encourage validation implementation medicine.

Language: Английский

Citations

0
Selexipag in Patients With Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials DOI

Jinlv Qin,

Guizuo Wang,

Dong Han

et al.

Current Problems in Cardiology, Journal Year: 2022, Volume and Issue: 48(2), P. 101466 - 101466

Published: Oct. 23, 2022

Language: Английский

Citations

12
Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta‐analysis DOI
Wenli Shang,

Yingying Zhang,

Dong Han

et al.

Clinical Cardiology, Journal Year: 2022, Volume and Issue: 45(10), P. 995 - 1001

Published: Aug. 2, 2022

Abstract Considering the prevalence of dyspnea in acute heart failure (AHF), its reduction is important to both patients and caregivers. This meta‐analysis was performed determine efficacy safety tolvaptan on early relief with AHF. A systematic search made PubMed, Embase, Web Science, Cochrane Library, clinicaltrials.gov , without language restrictions. Randomized controlled trials (RCTs) treatment AHF tolvaptan, compared placebo or blank, were reviewed. Studies pooled relative risk (RR), 95% confidence interval (CI). Five RCTs (enrolling 4857 participants) met inclusion criteria. Tolvaptan presented significant effects 12 h (RR: 1.98; CI: 1.24−3.15; p = .004), 24 h/day 1 1.15; 1.07−1.24; .0003), 48 1.20; 1.06−1.36; 72 1.18; 1.02−1.37; .03). No increase noticed incidence worsening renal function group 1.10; 0.87−1.39; .43). significantly improved patient‐assessed persistently

Language: Английский

Citations

9
Benefits of ozone on mortality in patients with COVID-19: A systematic review and meta-analysis DOI Creative Commons
Wenli Shang, Yan Wang,

Guizuo Wang

et al.

Complementary Therapies in Medicine, Journal Year: 2022, Volume and Issue: 72, P. 102907 - 102907

Published: Dec. 10, 2022

The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. Ozone therapy has long been used in treatment of a variety infectious diseases, probably through its antioxidant properties supply oxygen hypoxic tissues. This systematic review meta-analysis aimed determine efficacy ozone on mortality patients with COVID-19.A search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov, without language restrictions. Prospective controlled trials COVID-19 ozone, compared placebo or blank, were reviewed. Studies pooled risk ratios (RRs) weighted mean differences (WMDs), 95% confidence intervals (CIs).Eight (enrolling 371 participants) met inclusion criteria. showed significant effects (RR 0.38, CI 0.17-0.85; P = 0.02), length hospital stay (WMD -1.63 days, -3.05 -0.22 days; polymerase chain reaction (PCR) positivity 0.07, 0.01-0.34; 0.001).Ozone significantly reduced mortality, PCR positivity, hospitalized COVID-19. should be considered for patients.

Language: Английский

Citations

9
Long‐term safety of macitentan in patients with pulmonary hypertension: A meta‐analysis of randomised controlled trials DOI

Guizuo Wang,

Jinlv Qin,

Dong Han

et al.

European Journal of Clinical Investigation, Journal Year: 2023, Volume and Issue: 53(11)

Published: July 1, 2023

Abstract Background Macitentan has demonstrated its effectiveness in patients with pulmonary hypertension (PH), but safety, especially for long‐term use, needs to be further explored. This systematic review and meta‐analysis aimed determine the safety of use macitentan PH. Methods A search was made PubMed, Embase, Cochrane Library clinicaltrials.gov , without language restrictions. Randomised controlled trials (RCTs) on treatment PH macitentan, compared placebo, were reviewed. Estimated effects included studies pooled as risk ratios (RRs), 95% confidence intervals (CIs). Results Six RCTs (enrolling 1003 participants) met inclusion criteria. Anaemia (RR 3.86, CI 2.05–7.30), headache 1.52, 1.02–2.26) bronchitis 2.24, 1.30–3.87) more frequent groups. There no statistically significant difference proportion at least one adverse event (AE) or serious (SAE), AEs leading discontinuation study treatment, all‐cause death, right ventricular failure (RVF) peripheral oedema between two Conclusions The is safe PH, although a higher anaemia, bronchitis.

Language: Английский

Citations

3
Inhaled corticosteroids on mortality in COVID-19: A systematic review and meta-analysis of randomized controlled trials DOI

Fen Yang,

Guizuo Wang,

Dong Han

et al.

Journal of Investigative Medicine, Journal Year: 2024, Volume and Issue: 72(6), P. 567 - 573

Published: May 15, 2024

This systematic review and meta-analysis aimed to determine the efficacy of inhaled corticosteroids (ICS) on mortality in patients with coronavirus disease-2019 (COVID-19). A search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) treatment COVID-19 ICS were reviewed. Studies pooled risk ratios (RRs), 95% confidence intervals (CIs). Eleven RCTs (enrolling 5832 participants) met inclusion criteria. There no statistically significant difference COVID-19-related death (RR 0.88, CI 0.38–2.04), all-cause 1.05, 0.49–2.23), invasive ventilation 1.26, 0.60–2.62) between two groups. not associated reduced COVID-19.

Language: Английский

Citations

0
The Effect of Breathing and Relaxation Exercises on Self-Care, Dyspnea, and Fatigue in Heart Failure DOI

Gürcan Solmaz,

Mukadder Mollaoğlu, Ramazan Asoğlu

et al.

Holistic Nursing Practice, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 24, 2024

Dyspnea, fatigue, and self-care are common occurrences of heart failure. This study evaluated the effects yoga breathing progressive muscle relaxation exercises on dyspnea, in The conducted between April 2023 March 2024 randomized 66 failure patients into 3 groups (yoga exercise, control). intervention engaged specific tailored to their assigned regimen for 10 minutes twice daily over a 2-week period, while control group maintained pharmacological treatment. At end (second week) exercise notably ameliorated ( P < .001), changes saturation, rate, respiratory rate favoring .05). Yoga enhance self-care, alleviate dyspnea Additionally, provide benefits regulating

Language: Английский

Citations

0
Comment on: Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta‐analysis DOI Creative Commons
Cong Yin, Juan Li, Lin Yuan

et al.

Clinical Cardiology, Journal Year: 2023, Volume and Issue: 46(5), P. 584 - 584

Published: March 2, 2023

With great interest, we read the article by Shang et al.1 published in August 2022 Clinical Cardiology. The authors performed a meta-analysis and concluded that “tolvaptan treatment significantly improved patient-assessed dyspnea early persistently patients with acute heart failure.” At outset, would like to congratulate for writing an informative novelty. Nevertheless, have several suggestions queries communicate authors. First, evaluate quality of included studies using Detsky Quality Assessment Scale. Although this scale is used risk bias assessment, National Institutes Health Cochrane Library suggest qualitative analysis question. tool has become standard method experimental studies.2 Moreover, selection more definite approaches, such as GRADE (Grading Recommendations Assessment, Development Evaluation) approach, highly suggested define level evidence. Second, mentioned four databases clinicaltrials.gov were searched study, no language restrictions. It made results convincing if had other Wanfang Data, Scopus, China Knowledge Infrastructure (CNKI), World Organization Trials Portal (ICTRP) obtain literature Chinese or language. chances articles languages being ignored may be further narrowed. Third, did not register protocol International Prospective Register Systematic Reviews (PROSPERO). Protocol registration now recognized desirable approach enhance maintain transparency process assist minimizing selective outcome reporting bias.3 Fourth, need detailed retrieval strategies repeat meta-analysis. But paper provide it. And according requirements Preferred Reporting Items reviews Meta-Analyses (PRISMA), should provided article.4 same time, PRISMA been updated 2020 reflect recent advances systematic review methodology terminology,3 can use latest statement complete meta-analyses. In summary, learned author's standardized process. We hope discuss about above doubts. think our discussion make conclusion rigorous. declare conflict interest.

Language: Английский

Citations

1